HAMP and plasma cell myeloma: Clinical and laboratory evidence [36,40] suggests a possible use of hepcidin as a predictive marker for the response to the treatment with epoetin in patients with solid tumors (lung cancer, multiple myeloma, non-Hodgkin's lymphoma, mixed tumors).